PeptideStack
5.2kquestions
20kanswers
220users

Why did my lipase move after two weeks on survodutide?

Asked 18 Nov 2025Modified 5 months agoViewed 27k times
29

What I am working with: lipase · two weeks · survodutide.

This is not behaving the way I expected and I want to understand the discrepancy before I act on it.

I have photographed the current state and recorded the conditions, so I can answer follow-up questions precisely.

How do I distinguish the benign explanation from the one that matters?

bloodwork
bloodwork

Laboratory monitoring: which panels are worth ordering, sensible intervals, reference-range versus optimal-range arguments, and how to read a…

296 questions
kidney-function
kidney-function

eGFR, creatinine, cystatin C and albuminuria: the acute haemodynamic dip that is not injury, the renal outcome data from the FLOW programme, and…

141 questions
lipids
lipids

Lipid response on treatment: triglycerides, LDL-C, non-HDL-C, ApoB and Lp(a), which of them move with weight loss, and why a fasting panel drawn…

139 questions
pancreatitis
pancreatitis

Acute pancreatitis as a labelled risk: background incidence, the signal in pooled trial and pharmacovigilance data, lipase interpretation, and the…

30 questions
survodutide
survodutide

A GLP-1 and glucagon receptor dual agonist with a substantial published MASH dataset. Use this tag for its hepatic endpoints, its dose ladder, and…

225 questions
shareeditfollowflag
MH
askedm_haraldsen21k2718 Nov 2025
6Worth adding the time of day, since a couple of these have a diurnal swing. – laminar_bench 10 months ago
7Voting to keep this open — it is more specific than it first looks. – net_peptide 2 months ago
add a comment

5 Answers

Accepted answer first, then by votes
46

Accepted answer

2 weeks is 14 days, and the first question about any marker is whether 14 days is long enough for it to have finished moving. Lipase has a wide reference interval and a wider asymptomatic one, which makes an isolated value without symptoms a weak test in this setting. Against 14 days the marker is at or near the edge of its own settling time, so part of what you are reading is the transition rather than the destination. The second question is the denominator. Weight loss moves plasma volume, muscle mass and intake at once, and several of the markers on a routine panel are ratios with one of those three underneath them. Repeat before interpreting. A single value 14 days in, with no baseline drawn under the same conditions, is a number rather than a change — and nothing here is medical advice.

Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

Headline results, principal programmes

TrialAgentnDurationPrimary result
STEP 1Semaglutide 2.4 mg1,96168 wk−14.9 % vs −2.4 % weight
STEP 2Semaglutide 2.4 mg, T2DM1,21068 wk−9.6 % vs −3.4 % weight
SURMOUNT-1Tirzepatide 5/10/15 mg2,53972 wk−15 / −19 / −21 % weight
SURMOUNT-4Tirzepatide, withdrawal67088 wkContinued loss vs substantial regain
SELECTSemaglutide 2.4 mg17,604~40 moMACE HR 0.80 (0.72–0.90)
FLOWSemaglutide 1.0 mg, CKD3,533~3.4 yrRenal composite reduced; stopped early
SURMOUNT-OSATirzepatide, OSA46952 wkAHI reduced with and without PAP

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Keep the full report, not the number. You will need the units and the interval later.

shareimprove this answerflag
LQ
answered · acceptedlipid_panel_q36k12722 Nov 2025
Sponsored

Janoshik Analytical - Independent Third-Party Testing

HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.

Submit a sample
Sponsored — paired listing

GL Biochem (Shanghai) Ltd. - Direct Synthesis

Founded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.

Visit GL Biochem
40

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.

Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Same laboratory, same time, same fasting state, or the comparison is not a comparison.

shareimprove this answerflag
DA
answeredDr_Rosalind_Achebe69k14711 Mar 2026
21

This is answerable, and the answer is mostly about which tests rather than how many.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

shareimprove this answerflag
DV
answeredDr_Bram_Verhoeven84k2483 Dec 2025
17

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.

Reference intervals are conventionally the central ninety-five per cent of a reference population, which is the direct cause of the one-in-twenty out-of-range rate on a healthy panel.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

edited 26 Dec 2025 by lipid_panel_q — added the placebo-arm figures

shareimprove this answerflag
LQ
answeredlipid_panel_q36k12714 Dec 2025
Is the assay method stated on your report? Two immunoassays for the same analyte do not agree with each other. – j_wierzbicki 3 months ago
add a comment
12

Standardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

Decide the action for each result before you order the test.

edited 11 Jan 2026 by Dr_Ravi_Selvarajah — updated for the 2026 guidance change

shareimprove this answerflag
DS
answeredDr_Ravi_Selvarajah35k13725 Dec 2025
4Minor: haemolysis inflates potassium enough to cause a fright over what is a handling artefact. – tess_amankwah 5 months ago
5Worth flagging that a mild enzyme elevation with a normal bilirubin is a different object from a rising one. – h_pergande 6 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.